Novo Nordisk, a leading pharmaceutical company, has taken legal action against Hims & Hers, an online telehealth provider, for offering cheaper, unapproved versions of its popular Wegovy obesity pill and injections. The lawsuit seeks to protect the company's patents and prevent potential harm to patients. Novo Nordisk's legal team argues that Hims & Hers' compounded drugs are untested and pose risks to consumers, as their safety, efficacy, and quality are not regulated by U.S. authorities. This move marks an escalation in the ongoing feud between the two companies, with Hims & Hers initially planning to offer a copycat pill at a significantly lower price than the approved Wegovy. The lawsuit comes at a time when Novo Nordisk is working to maintain its market share in the obesity drug sector, facing competition from Eli Lilly and compounded alternatives. Despite the resolution of the semaglutide shortage, Novo Nordisk estimates that around 1.5 million Americans use compounded GLP-1 drugs. Hims & Hers has defended its actions, claiming its compounded pill is legal due to personalized dosing. However, Novo Nordisk refutes this, accusing Hims & Hers of engaging in illegal mass compounding. The Food and Drug Administration has also taken action, announcing plans to restrict access to ingredients used in non-approved compounded drugs and referring Hims & Hers to the Department of Justice. Novo Nordisk's legal strategy aims to curb the proliferation of compounded drugs and protect patients from potential risks, while also addressing deceptive marketing practices and consumer fraud.
